PDF
ESMO Asia 2018
Daily reports from ASH 2018 by Springer Healthcare
Daily report from the first three days of ASH 2018. Read more
Presentations
-
PDFNov 23, 2018 | Oncology ESMO Asia 2018
Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
-
PDFNov 23, 2018 | Lung Cancer ESMO Asia 2018
ESMO-Asia Oral IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations
-
PDFNov 24, 2018 | Lung Cancer ESMO Asia 2018
ESMO Asia oral IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
-
PDFNov 24, 2018 | Lung Cancer ESMO Asia 2018
Primary results of ALESIA: a randomised, phase III, open-label study of alectinib versus crizotinib in Asian patients with treatment-niave ALK+ advanced NSCLC
-
PDFNov 25, 2018 | Oncology ESMO Asia 2018
ESMO-Asia Oral 2018 Atezolizumab + bevacizumab in hepatocellular carcinoma: safety and clinical activity results from a Phase Ib study
-
PDFNov 24, 2018 | Oncology ESMO Asia 2018
ESMO-Asia Oral 2018 Atezolizumab monotherapy in Chinese patients with locally advanced or metastatic solid tumours